Acute Rejection of Renal Transplant

2

Review clinical trials related to Acute Rejection of Renal Transplant. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function. Donor-derived cell-free DNA (ddcfDNA) is a promising method to do so as it is elevated prior to acute rejection and has good predictive performance especially for antibody-mediated and high severity T-cell mediated rejection. Its ability to predict low severity T-cell mediated rejection and future graft function remains equivocal. Regulatory T cells (Tregs) are essential in transplant tolerance by suppressing effector immune responses. Circulating post-transplant highly suppressive HLA-DR+ Tregs were reduced in recipients who developed acute rejection. Preliminary results in a cohort including predominantly low severity T-cell mediated rejection also showed that pre-transplant circulating highly suppressive TNFR2+ Tregs were reduced in and could predict acute rejection. Integrating dd-cfDNA with HLA-DR+TNFR2+ Treg could improve the predictive performance for acute rejection especially of low severity and potentially predict graft function. Plasma dd-cfDNA and HLA-DR+TNFR2+ Tregs will be measured in 150 kidney transplant recipients at scheduled intervals during the first 6 months post-transplant. Predictive accuracy of a model integrating ddcfDNA and HLA-DR+TNFR2+ Treg for acute rejection will be tested using ROC curve analysis and multivariate logistic regression. Predictive accuracy for 1-year graft function will be tested using multivariate linear regression. High predictive performance for acute rejection and graft function using a model integrating dd-cfDNA and HLA-DR+TNFR2+ Treg would help identify kidney transplant recipients at immunologic risk early on and allow personalization of immunosuppression accordingly.

Participants needed: 150
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Loma Linda UniversityUpdated: Aug 7, 2025Locations: 1
Eligibility criteria

Adult kidney transplant candidates/recipients

Age less than 18 [+3]

Status: Not yet recruiting

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf

SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate long term outcomes on an observational basis.

Participants needed: 1,000
Trial details
Age: 65+Biological sex: AllType: ObservationalSponsor: Klemens BuddeUpdated: Aug 12, 2016Duration: 10 Years
Eligibility criteria

Males or females, aged ≥65 years [+5]

Multi-organ recipients (solid organ or bone marrow) [+10]